铁死亡在泌尿系统肿瘤中的作用及其机制研究进展

doi:10.11904/j.issn.1002-3070.2023.01.013

摘要/Abstract

摘要： 铁死亡是近年来新发现的一种不同于凋亡、坏死和自噬的程序性细胞死亡。细胞内谷胱甘肽及谷胱甘肽过氧化物酶抗氧化防御系统调控异常及铁离子依赖性膜结构脂质过氧化的蓄积是铁死亡发生的主要病理生理改变。铁死亡参与包括肿瘤、缺血再灌注损伤及神经系统疾病等多种疾病的发生发展过程。近年来研究发现铁死亡与泌尿系统肿瘤密切相关,本文概述了铁死亡在泌尿系统肿瘤发生及进展中作用的相关调控分子机制,旨在为泌尿系统肿瘤的临床治疗提供新的方向。

关键词: 铁死亡, 泌尿系统, 肿瘤

Abstract: Ferroptosis is a newly discovered programmed cell death in recent years,which is different from apoptosis,necrosis and autophagy.Abnormal regulation of intracellular glutathione or glutathione peroxidase antioxidant defense system and accumulation of iron iron-dependent membrane structure lipid peroxidation are the main pathophysiological changes of ferroptosis.Ferroptosis is involved in the occurrence and development of various diseases including tumors,ischemia-reperfusion injuries and neurological diseases.In recent years,studies have found that ferroptosis is closely related to urinary system tumors.This paper summarizes the relevant regulatory molecular mechanisms of ferroptosis in the occurrence and progression of urinary system tumors,aiming to provide a new direction for the clinical treatment of urinary system tumors.

Key words: Ferroptosis, Urinary system, Tumor

中图分类号:

R737.1

朱兴, 张冰, 赵静, 纪洪. 铁死亡在泌尿系统肿瘤中的作用及其机制研究进展[J]. 实用肿瘤学杂志, 2023, 37(1): 73-78.

ZHU Xing, ZHANG Bing, ZHAO Jing, JI Hong. Research progress on the role and mechanism of ferroptosis in urinary neoplasms[J]. Journal of Practical Oncology, 2023, 37(1): 73-78.

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Jiang X,Stockwell BR,Conrad M.Ferroptosis:Mechanisms,biology and role in disease[J].Nat Rev Mol Cell Biol,2021,22(4):266-282.
3 Lei G,Zhuang L,Gan B.Targeting ferroptosis as a vulnerability in cancer[J].Nat Rev Cancer,2022,22(7):381-396.
4 Conrad M,Pratt DA.The chemical basis of ferroptosis[J].Nat Chem Biol,2019,15(12):1137-1147.
5 Yang WS,Kim KJ,Gaschler MM,et al.Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis[J].Proc Natl Acad Sci U S A,2016,113(34):4966-4975.
6 Gao G,Li J,Zhang Y,et al.Cellular iron metabolism and regulation[J].Adv Exp Med Biol,2019,1173:21-32.
7 Hou W,Xie Y,Song X,et al.Autophagy promotes ferroptosis by degradation of ferritin[J].Autophagy,2016,12(8):1425-1428.
8 Chang LC,Chiang SK,Chen SE,et al.Heme oxygenase-1 mediates bay 11-7085 induced ferroptosis[J].Cancer Lett,2018,416:124-137.
9 Kajarabille N,Latunde-Dada GO.Programmed cell-death by ferroptosis:Antioxidants as mitigators[J].Int J Mol Sci,2019,20(19):4968.
10 Gao M,Yi J,Zhu J,et al.Role of mitochondria in ferroptosis[J].Mol Cell,2019,73(2):354-363.
11 Seibt TM,Proneth B,Conrad M.Role of gpx4 in ferroptosis and its pharmacological implication[J].Free Radic Biol Med,2019,133:144-152.
12 Koppula P,Zhuang L,Gan B.Cystine transporter slc7a11/xct in cancer:Ferroptosis,nutrient dependency,and cancer therapy[J].Protein Cell,2021,12(8):599-620.
13 Chen X,Kang R,Kroemer G,et al.Broadening horizons:The role of ferroptosis in cancer[J].Nat Rev Clin Oncol,2021,18(5):280-296.
14 Xie Y,Hou W,Song X,et al.Ferroptosis:Process and function[J].Cell Death Differ,2016,23(3):369-379.
15 Hamazaki S,Okada S,Ebina Y,et al.Nephrotoxicity of ferric nitrilotriacetate.An electron-microscopic and metabolic study[J].Am J Pathol,1986,123(2):343-350.
16 Yang WS,Sriramaratnam R,Welsch ME,et al.Regulation of ferroptotic cancer cell death by gpx4[J].Cell,2014,156(1-2):317-331.
17 Zou Y,Palte MJ,Deik AA,et al.A gpx4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis[J].Nat Commun,2019,10(1):1617.
18 Yu R,Zhou Y,Shi S,et al.Icariside ii induces ferroptosis in renal cell carcinoma cells by regulating the mir-324-3p/gpx4 axis[J].Phytomedicine,2022,102:154182.
19 Lu Y,Qin H,Jiang B,et al.Klf2 inhibits cancer cell migration and invasion by regulating ferroptosis through gpx4 in clear cell renal cell carcinoma[J].Cancer Lett,2021,522:1-13.
20 Jia L,Carlo MI,Khan H,et al.Distinctive mechanisms underlie the loss of smarcb1 protein expression in renal medullary carcinoma:morphologic and molecular analysis of 20 cases[J].Mod Pathol,2019,32(9):1329-1343.
21 Tourigny DS,Zucker M,Kim M,et al.Molecular characterization of the tumor microenvironment in renal medullary carcinoma[J].Front Oncol,2022,12:910147.
22 Nguyen CDK,Yi C.Yap/taz signaling and resistance to cancer therapy[J].Trends Cancer,2019,5(5):283-296.
23 Yang WH,Ding CC,Sun T,et al.The hippo pathway effector taz regulates ferroptosis in renal cell carcinoma[J].Cell Rep,2019,28(10):2501-2508.
24 Xu CL,Chen L,Li D,et al.Acyl-coa thioesterase 8 and 11 as novel biomarkers for clear cell renal cell carcinoma[J].Front Genet,2020,11:594969.
25 Wu G,Wang Q,Xu Y,et al.A new survival model based on ferroptosis-related genes for prognostic prediction in clear cell renal cell carcinoma[J].Aging(Albany NY),2020,12(14):14933-14948.
26 Santana-Codina N,Gikandi A,Mancias JD.The role of ncoa4-mediated ferritinophagy in ferroptosis[J].Adv Exp Med Biol,2021,1301:41-57.
27 Mou Y,Wu J,Zhang Y,et al.Low expression of ferritinophagy-related ncoa4 gene in relation to unfavorable outcome and defective immune cells infiltration in clear cell renal carcinoma[J].BMC Cancer,2021,21(1):18.
28 Beretta GL,Zaffaroni N.Androgen receptor-directed molecular conjugates for targeting prostate cancer[J].Front Chem,2019,7:369.
29 Kumari S,Sharma V,Tiwari R,et al.Therapeutic potential of p53 reactivation in prostate cancer:strategies and opportunities[J].Eur J Pharmacol,2022,919:174807.
30 Zhou X,Zou L,Chen W,et al.Flubendazole,fda-approved anthelmintic,elicits valid antitumor effects by targeting p53 and promoting ferroptosis in castration-resistant prostate cancer[J].Pharmacol Res,2021,164:105305.
31 Liao D,Yang G,Yang Y,et al.Identification of pannexin 2 as a novel marker correlating with ferroptosis and malignant phenotypes of prostate cancer cells[J].Onco Targets Ther,2020,13:4411-4421.
32 Dodson M,Castro-Portuguez R,Zhang DD.Nrf2 plays a critical role in mitigating lipid peroxidation and ferroptosis[J].Redox Biol,2019,23:101107.
33 Jiang X,Guo S,Xu M,et al.Tfap2c-mediated lncrna pcat1 inhibits ferroptosis in docetaxel-resistant prostate cancer through c-myc/mir-25-3p/slc7a11 signaling[J].Front Oncol,2022,12:862015.
34 Yadav S,Chawla B,Khursheed MA,et al.The glutathione degrading enzyme,chac1,is required for calcium signaling in developing zebrafish:Redox as an upstream activator of calcium[J].Biochem J,2019,476(13):1857-1873.
35 Perra L,Balloy V,Foussignière T,et al.Chac1 is differentially expressed in normal and cystic fibrosis bronchial epithelial cells and regulates the inflammatory response induced by pseudomonas aeruginosa[J].Front Immunol,2018,9:2823.
36 He S,Zhang M,Ye Y,et al.Chac glutathione specific γ-glutamylcyclotransferase 1 inhibits cell viability and increases the sensitivity of prostate cancer cells to docetaxel by inducing endoplasmic reticulum stress and ferroptosis[J].Exp Ther Med,2021,22(3):997.
37 Heidelberger JB,Voigt A,Borisova ME,et al.Proteomic profiling of vcp substrates links vcp to k6-linked ubiquitylation and c-myc function[J].EMBO Rep,2018,19(4):e44754.
38 Ogor P,Yoshida T,Koike M,et al.Vcp relocalization limits mitochondrial activity,gsh depletion and ferroptosis during starvation in pc3 prostate cancer cells[J].Genes Cells,2021,26(8):570-582.
39 Duscharla D,Reddy Kami Reddy K,Dasari C,et al.Interleukin-6 induced overexpression of valosin-containing protein(vcp)/p97 is associated with androgen-independent prostate cancer(aipc)progression[J].J Cell Physiol,2018,233(10):7148-7164.
40 Blomme A,Ford CA,Mui E,et al.2,4-dienoyl-coa reductase regulates lipid homeostasis in treatment-resistant prostate cancer[J].Nat Commun,2020,11(1):2508.
41 Nassar ZD,Mah CY,Dehairs J,et al.Human decr1 is an androgen-repressed survival factor that regulates pufa oxidation to protect prostate tumor cells from ferroptosis[J].Elife,2020,9:e54166.
42 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
43 Yan Y,Cai J,Huang Z,et al.A novel ferroptosis-related prognostic signature reveals macrophage infiltration and emt status in bladder cancer[J].Front Cell Dev Biol,2021,9:712230.
44 Yang L,Li C,Qin Y,et al.A novel prognostic model based on ferroptosis-related gene signature for bladder cancer[J].Front Oncol,2021,11:686044.
45 Luan JC,Zeng TY,Zhang QJ,et al.A novel signature constructed by ferroptosis-associated genes(fags)for the prediction of prognosis in bladder urothelial carcinoma(blca)and associated with immune infiltration[J].Cancer Cell Int,2021,21(1):414.
46 Liang Y,Ye F,Xu C,et al.A novel survival model based on a ferroptosis-related gene signature for predicting overall survival in bladder cancer[J].BMC Cancer,2021,21(1):943.
47 Cui Y,Zhou Z,Chai Y,et al.Identification of a nomogram from ferroptosis-related long noncoding rnas signature to analyze overall survival in patients with bladder cancer[J].J Oncol,2021,2021:8533464.
48 Jasim KA,Gesquiere AJ.Ultrastable and biofunctionalizable conjugated polymer nanoparticles with encapsulated iron for ferroptosis assisted chemodynamic therapy[J].Mol Pharm,2019,16(12):4852-4866.
49 Chen JN,Li T,Cheng L,et al.Synthesis and in vitro anti-bladder cancer activity evaluation of quinazolinyl-arylurea derivatives[J].Eur J Med Chem,2020,205:112661.
50 Kong N,Chen X,Feng J,et al.Baicalin induces ferroptosis in bladder cancer cells by downregulating fth1[J].Acta Pharm Sin B,2021,11(12):4045-4054.
51 Xiang Y,Chen X,Wang W,et al.Natural product erianin inhibits bladder cancer cell growth by inducing ferroptosis via nrf2 inactivation[J].Front Pharmacol,2021,12:775506.
52 Luo W,Wang J,Xu W,et al.Lncrna rp11-89 facilitates tumorigenesis and ferroptosis resistance through prom2-activated iron export by sponging mir-129-5p in bladder cancer[J].Cell Death Dis,2021,12(11):1043.

[1]	杨建华, 罗赛美, 龙欣甜, 李蔚, 杨璧榕, 余龙涛, 张腾, 文洪梅. 2017年云南省肿瘤登记地区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2023, 37(1): 6-10.
[2]	马骥雄, 马菊红, 周红, 鲁朝霞, 丁高恒, 刘玉琴. 2018年甘肃省白银市恶性肿瘤发病和死亡分析[J]. 实用肿瘤学杂志, 2023, 37(1): 11-16.
[3]	蔡圻锐, 于晓兰, 刘家仁. 香叶醇抗肿瘤活性及其他生物学作用的研究进展[J]. 实用肿瘤学杂志, 2023, 37(1): 58-62.
[4]	李书桢, 蔡志福, 容雁, 庞业滨, 罗冬妮, 高琨. 肿瘤体积在宫颈癌近距离治疗中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(1): 63-67.
[5]	曹文杰, 魏瑗, 邝栋明. 肿瘤浸润B细胞与免疫治疗[J]. 实用肿瘤学杂志, 2022, 36(6): 507-512.
[6]	张玥, 汪越, 魏嘉. SHP2作为抗肿瘤治疗靶点的价值及其在肿瘤免疫治疗中的应用[J]. 实用肿瘤学杂志, 2022, 36(6): 513-519.
[7]	那睿思, 郭影, 时佳琪, 郑桐森. 小肠肿瘤罕见原因[J]. 实用肿瘤学杂志, 2022, 36(6): 526-530.
[8]	王馨艺, 路一平, 孙峥嵘. m6A RNA甲基化修饰影响恶性肿瘤及肿瘤干细胞生物学特性的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 551-555.
[9]	张淑敏, 张弓. ILC2s在肿瘤免疫调控中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 566-569.
[10]	朱开彬, 贺长军, 陈澜涛, 孔祥龙, 赵苏, 徐世东. TAM通过PLGF/Flt-1和TGF-β1通路促进非小细胞肺癌生长和肿瘤血管异生的研究[J]. 实用肿瘤学杂志, 2022, 36(5): 391-397.
[11]	王钦, 刘军杰, 陆秀鑫, 吴雅菲, 张文皓. 基于铁死亡的纳米联合疗法在恶性肿瘤治疗中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 429-434.
[12]	黄永平, 李梦洁, 孙玉芳, 项涛. 细菌生物膜在肿瘤生物学进程及治疗应用中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 440-444.
[13]	何晓晴, 柯鹏, 张新友. BCL-2抑制剂在血液恶性肿瘤中的靶向治疗应用及作用机制[J]. 实用肿瘤学杂志, 2022, 36(5): 452-457.
[14]	李雄, 姜文凯, 郎泽昆, 芮少珍. 肿瘤相关中性粒细胞与胰腺癌关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 458-462.
[15]	李鑫林, 周金意, 韩仁强, 蔡波, 徐红, 韩颖颖. 2013—2017年南通市肺癌流行病学特征分析[J]. 实用肿瘤学杂志, 2022, 36(4): 304-309.